Is the BioNTech-Pfizer COVID-19 vaccination effective in elderly populations? Results from population data from Bavaria, Germany

Delphina Gomes1¶, Andreas Beyerlein1¶, Katharina Katz2, Gabriele Hoelscher2, Uta Nennstiel2, Bernhard Liebl2, Klaus Überla3, Rüdiger von Kries1\*

1 Institute of Social Pediatrics and Adolescent Medicine, Division of Pediatric Epidemiology, Ludwig-Maximilians-University, Munich, Germany

2 Bavarian Health and Food Safety Authority, Oberschleissheim, Germany

3 Institute of Clinical and Molecular Virology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

**\***[ruediger.kries@med.uni-muenchen.de](mailto:ruediger.kries@med.uni-muenchen.de)

¶These authors contributed equally to this work.

**S1 Figure. Vaccine efficacy to prevent COVID-19 infection and related outcomes after at least one BNT162b2 vaccine dose compared to none in Bavarian persons aged 80 years and above.**

Vaccine efficacy was calculated as 1 – HR and are adjusted for sex. CI, confidence interval; HR, hazards ratio; VE, vaccine efficacy.